Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cardiotoxicity × Spironolactone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 9 Neoplasms 4 Hyperandrogenism 4 Inflammation 2 Heart Failure 2 Urinary Tract Infections 1 Triple Negative Breast Neoplasms 1 Staphylococcal Infections 1 Spasm 1 Sleep Initiation and Maintenance Disorders 1 Skin Diseases 1 Sepsis 1 Seizures 1 Schizophrenia, Treatment-Resistant 1 Schizophrenia 1 Retinitis 1 Renal Insufficiency, Chronic 1 Rare Diseases 1 Pulmonary Arterial Hypertension 1 Pneumonia 1 Pain 1 Obesity 1 Neutropenia 1 Neoplasm Metastasis 1 Migraine Disorders 1 Metabolic Syndrome 1 Menorrhagia 1 Meningitis, Bacterial 1 Meningitis 1 Leukemia, Myeloid, Acute 1

Interventions

Doxorubicin 15 Echocardiography 13 Exercise 8 Electrocardiography 7 Dexrazoxane 7 Cyclophosphamide 7 Trastuzumab 6 Razoxane 5 Carvedilol 5 Vincristine 4 Filgrastim 4 Radiotherapy 3 Methotrexate 3 Granulocyte Colony-Stimulating Factor 3 Etoposide 3 Docetaxel 3 Cisplatin 3 Atorvastatin 3 salicylhydroxamic acid 2 sacubitril and valsartan sodium hydrate drug combination 2 empagliflozin 2 Tablets 2 Social Determinants of Health 2 Prednisone 2 Magnetic Resonance Spectroscopy 2 Leucovorin 2 Ivabradine 2 High-Intensity Interval Training 2 Chemotherapy, Adjuvant 2 Blood Specimen Collection 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06005259 2023-08-22

SPIROTOX

University of Sao Paulo

Phase 4 Unknown

Heart Failure, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡